Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.88M Buy
11,463
+187
+2% +$40.2K 1.25% 26
2026
Q1
$2.45M Buy
11,276
+259
+2% +$57.5K 1.22% 26
2025
Q4
$2.52M Buy
11,017
+144
+1% +$32.8K 1.18% 30
2025
Q3
$2.52M Buy
10,873
+350
+3% +$71.3K 1.23% 30
2025
Q2
$1.95M Buy
10,523
+20
+0.2% +$3.72K 1.03% 40
2025
Q1
$1.86M Buy
10,503
+48
+0.5% +$9.33K 1.15% 34
2024
Q4
$1.86M Buy
+10,455
New +$1.92M 1.13% 39

Other funds holding ABBV

AGP Franklin's ABBV Position: Q2 2026 in Review

AGP Franklin increased its AbbVie (ABBV) stake by 1.7% in Q2 2026, buying an estimated $40.2K and bringing the position to 11,463 shares worth $2.88M. The position accounts for 1.25% of the portfolio, ranked #26.

AGP Franklin first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. 4,207 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • AGP Franklin held 11,463 shares of AbbVie worth $2.88M as of Q2 2026.
  • AGP Franklin bought 187 AbbVie shares in Q2 2026, an estimated $40.2K.
  • AbbVie made up 1.25% of AGP Franklin's portfolio in Q2 2026, its #26 holding.
  • AGP Franklin first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • 4,207 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on AGP Franklin's 13F filing for Q2 2026, filed 30 Jul 2026.